.

Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Dow
Cantor Fitzgerald
McKesson
Federal Trade Commission
Cipla
Queensland Health
QuintilesIMS
Farmers Insurance
McKinsey
Johnson and Johnson

Generated: September 26, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Claims for Patent: ► Subscribe

Title: Stabilizers to prevent autoradiolysis of radiolabeled peptides and proteins
Abstract:Gentisic acid and its derivatives substantially inhibit peptide autoradiolysis. Gentisic acid or its derivatives may also be used in combination with other stabilizers such as inositol and ascorbic acid to inhibit autoradiolysis of radiolabeled peptides.
Inventor(s): Deutsch; Edward A. (Maryland Heights, MO), Goedemans; Wilhelmus T. (Bergen, NL), Maria de Jong; Martinus T. (Hoogkarspel, NL), Miller; Kathleen M. (St. Louis, MO), Brodack; James W. (Florissant, MO)
Assignee: Mallinckrodt Medical, Inc. (St. Louis, MO)
Application Number:08/135,882
Patent Claims: 1. A method of preventing autoradiolysis of radiolabeled peptides by including a stabilizer selected from the group consisting of gentisic acid, genetisyl alcohol and water soluble salts, esters, and mixtures thereof in a pharmaceutically acceptable carrier containing a biologically active peptide radiolabeled with a radionuclide selected from the group consisting of .sup.111 In, .sup.67 Ga, .sup.169 Yb, .sup.125 I, .sup.123 I, and .sup.201 Tl, wherein said stabilizer is present in an amount effective to prevent autoradiolysis of the radiolabeled biologically active peptide.

2. A method of preventing autoradiolysis of radiolabeled peptides as defined in claim 1, wherein the radiolabeled biologically active peptide is labeled with a radionuclide by use of a bifunctional chelate.

3. A method of preventing autoradiolysis of radiolabeled peptides as defined in claim 1, wherein the radiolabeled biologically active peptide is labeled with a radionuclide by direct labeling of the peptide.

4. A method of preventing autoradiolysis of radiolabeled peptides as defined in claim 1, wherein the pharmaceutically acceptable carrier further comprises a second stabilizer.

5. A method of preventing autoradiolysis of radiolabeled peptides as defined in claim 4, wherein the second stabilizer includes inositol.

6. A method of preventing autoradiolysis of radiolabeled peptides as defined in claim 4, wherein the second stabilizer includes ascorbic acid.

7. A method of preventing autoradiolysis of radiolabeled peptides as defined in claim 1, wherein the pharmaceutically acceptable carrier contains a buffer.

8. A method of preventing autoradiolysis of radiolabeled peptides as defined in claim 1, wherein the radionuclide is .sup.111 In.

9. A method of preventing autoradiolysis of radiolabeled peptides as defined in claim 8, wherein the peptide is octreotide.

10. A method of preventing autoradiolysis of radiolabeled proteins by including a stabilizer selected from the group consisting of gentisic acid, gentisyl alcohol and water soluble salts, esters, and mixtures thereof in a pharmaceutically acceptable carrier containing a biologically active protein radiolabeled with a radionuclide selected from the group consisting of .sup.111 In, .sup.67 Ga, .sup.169 Yb, .sup.125 I, .sup.123 I, and .sup.201 Tl, wherein said stabilizer is present in an amount effective to prevent autoradiolysis of the radiolabeled biologically active protein.

11. A method of preventing autoradiolysis of radiolabeled proteins as defined in claim 10, wherein the radiolabeled biologically active protein is labeled with a radionuclide by use of a bifunctional chelate.

12. A method of preventing autoradiolysis of radiolabeled proteins as defined in claim 10, wherein the radiolabeled biologically active protein is labeled with a radionuclide by direct labeling of the protein.

13. A method of preventing autoradiolysis of radiolabeled proteins as defined in claim 10, wherein the pharmaceutically acceptable carrier contains a buffer.

14. A method of preventing autoradiolysis of radiolabeled proteins as defined in claim 10, wherein the radionuclide is .sup.111 In.

15. A composition for preparing a radiolabeled octreotide preparation stable to autoradiolysis comprising:

a quantity of DTPA-octreotide, wherein the DTPA-octreotide is labeled with .sup.111 In; and

a stabilizer selected from the group consisting of gentisic acid, gentisyl alcohol, and the water soluble salts, esters, derivatives, and mixtures thereof.

16. A composition as defined in claim 15, further comprising a second stabilizer.

17. A composition as defined in claim 16, wherein the second stabilizer includes inositol.

18. A composition as defined in claim 16, wherein the second stabilizer includes ascorbic acid.

19. A composition as defined in claim 16, further comprising a buffer.

20. A composition as defined in claim 19, wherein the composition is in the form of a lyophilized kit.

21. A composition as defined in claim 15, wherein the composition is a liquid formulation.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Deloitte
Moodys
Farmers Insurance
Daiichi Sankyo
Baxter
Queensland Health
Express Scripts
Boehringer Ingelheim
Dow
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot